CHRS FY 2023 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$257M+21.9% YoY

Gross Profit

$98M38.2% margin

Operating Income

-$203M-79.0% margin

Net Income

-$238M-92.5% margin

EPS (Diluted)

$-2.53

Cash Flow

Operating Cash Flow

-$175M

Free Cash Flow

-$175M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$630M

Total Liabilities

$823M

Stockholders' Equity

-$193M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$257M	$211M	+21.9%
Gross Profit	$98M	$141M	-30.3%
Operating Income	-$203M	-$257M	+20.9%
Net Income	-$238M	-$292M	+18.5%